Development of LXR inverse agonists to treat MAFLD, NASH, and other metabolic diseases

Overview of attention for article published in Frontiers in Medicine, February 2023

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (81st percentile)
High Attention Score compared to outputs of the same age and source (86th percentile)

Mentioned by

news: 1 news outlet

Citations

dimensions_citation: 11 Dimensions

Readers on

mendeley: 12 Mendeley

Summary News Dimensions citations

So far, Altmetric has seen 1 news story.

OrsoBio to Present Phase 1 Data for the Liver-Targeted LXR Inverse Agonist TLC-2716 in Development for Severe Hypertriglyceridemia and NASH at AHA’s Scientific Sessions 2023

Yahoo! Finance USA, 06 Nov 2023

Data confirm the safety, tolerability, and lipid lowering benefits of TLC-2716 in healthy volunteers MENLO PARK, Calif.…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.